Which new GLP-1 drugs are coming next
No guessing, no tracking apps, no cooking
Endothelial progenitor cells as pathogenetic and diagnostic factors, and potential targets for GLP-1 in combination with metabolic syndrome and chronic obstructive pulmonary disease
History and lineage of Russian cognitive peptides The Russian neuropeptide school, founded by Nikolai Bechtereva and systematised by Ivan Ashmarin in the 1970s-1990s, rests on an original doctrine: each major endogenous neuropeptide carries within it short bioactive fragments capable of activating receptor subsets more selectively than the parent sequence
Glutathione responsive nanomedicine leverages tumor redox imbalance for targeted cancer theranostics
GLP-1 receptor agonist drugs such as semaglutide (Ozempic, Wegovy) and tirzepatide are praised for their appetite-suppressing effects and impressive short-term weight-loss outcomes